Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Federica Cocito, MD, Silvia Mangiacavalli, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5711.

https://doi.org/10.1182/blood.V128.22.5711.5711

Published: 2016

Journal Articles

Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors

Chiara Elena, MD, Anna Gallì, Antonio Bianchessi, Virginia Valeria Ferretti, PhD, Silvia Zibellini, Silvia Catricalà, Celeste Calvello, Barbara Rocca, Paolo Bernasconi, MD, Ettore Rizzo, Elisabetta Molteni, Luca Malcovati, MD, Matteo Giovanni Della Porta, Ester Maria Orlandi, MD, Mario Cazzola, MD

Blood (2016) 128 (22): 1117.

https://doi.org/10.1182/blood.V128.22.1117.1117

Published: 2016

Journal Articles

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Silvia Mangiacavalli, MD, Federica Cocito, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, MD, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5695.

https://doi.org/10.1182/blood.V128.22.5695.5695

Published: 2016

Journal Articles

Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Maria Luisa Guerrera, MD, Marzia Varettoni, MD, Alessandra Tedeschi, MD, Anna Maria Frustaci, MD, Virginia Valeria Ferretti, PhD, Luca Arcaini, Prof, Paola Picardi, MD, Silvia Zibellini, Sara Rattotti, MD, Roberto Cairoli, MD, Mario Cazzola, MD

Blood (2015) 126 (23): 5084.

https://doi.org/10.1182/blood.V126.23.5084.5084

Published: 2015

Journal Articles

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Patrizia Zappasodi, MD, Laura Marbello, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Massimo Bernardi, MD, Nicola Stefano Fracchiolla, MD, Matteo Da Vià, MD, Marianna Rossi, MD, Emanuele Ravano, MD, Elisa Cerqui, MD, Virginia Valeria Ferretti, PhD, Mario Cazzola, Prof, Carlo Castagnola, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3740.

https://doi.org/10.1182/blood.V126.23.3740.3740

Published: 2015

Journal Articles

Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.

Michele Merli, MD, Michele Spina, MD, Stefano Luminari, MD, Claudia Basilico, MD, Clara Targhetta, MD, Carlo Visco, MD, Alessandro Levis, MD, Davide Rossi, MD, Alfonso Maria D'Arco, MD, Luigi Rigacci, MD, Achille Ambrosetti, MD, Pellegrino Musto, MD, Alessandra Tucci, MD, Annalisa Chiappella, MD, Andrea Ferrario, MD, Sara Rattotti, MD, Virginia Valeria Ferretti, PhD, Cristiana Pascutto, PhD, Luca Arcaini, MD

Blood (2010) 116 (21): 2821.

https://doi.org/10.1182/blood.V116.21.2821.2821

Published: 2010

NARROW

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.

Email alerts

ASH Publications

American Society of Hematology

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only